GENE ONLINE|News &
Opinion
Blog

2021-08-22| ChinaSpecial

HebaBiz Biotech Obtains FDA Clearance to Trial Cancer Drug Against Aggressive Brain Tumor

by Rajaneesh K. Gopinath
Share To
Glioblastoma (GBM) is the most common and aggressive form of brain tumor with a poor prognosis. Existing treatment includes surgery, followed by radiotherapy, and chemotherapy. Yet, several patients develop resistance to treatments, suffer from relapse, and die, creating a significant unmet need in this area.

At this juncture, Beijing-based HebaBiz Biotech announces that the FDA has accepted IND for its innovative anti-cancer drug for Glioblastoma trials in the US.

GO Prime with only $1.49 now

SUBSCRIBE NOW
LATEST
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024-04-17
Rice University Engineers Develop Miniature Brain Stimulator for Safer and Less-invasive Neuromodulation
2024-04-17
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
2024-04-16
Join Us for the SABPA OC/LA 16th Annual Biomedical Forum!
2024-04-16
Sequencing Revolution Spotlights the Titans of NGS Innovation
2024-04-16
Oncology’s New Drugs on the Horizon (II): Radiotherapy, Radioligands & Other Therapeutic Agents
2024-04-12
READ MORE
EVENT
2024-04-20
16th SABPA OC/LA Annual Biomedical Forum
The Beckman Center, 100 Academy, Irvine, CA, 92617
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
SEE MORE
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2024 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top